Pathological and biochemical outcomes after radical prostatectomy in men with low‐risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteriaKoji Mitsuzuka, Yoichi Arai, Shintaro Narita et al.|British Journal of Urology|2013Cited by 49
Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomyTakuya Koie, Yuki Tobisawa, Koji Mitsuzuka et al.|International Journal of Clinical Oncology|2014Cited by 40
Clinical implications of serum <i>N‐</i>glycan profiling as a diagnostic and prognostic biomarker in germ‐cell tumorsTakuma Narita, Chikara Οhyama, Sadafumi Kawamura et al.|Cancer Medicine|2017Cited by 26
Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysisTakuya Koie, Yuki Tobisawa, Koji Mitsuzuka et al.|International Journal of Clinical Oncology|2015Cited by 23
Is pelvic lymph node dissection required at radical prostatectomy for low‐risk prostate cancer?Koji Mitsuzuka, Yoichi Arai, Takuya Koie et al.|International Journal of Urology|2013Cited by 22